A study looking at pembrolizumab for triple negative breast cancer (KEYNOTE-119)

This study was for people with triple negative breast cancer that had spread to other parts of the body. They had already had 1 or 2 treatments since the cancer had spread.

Triple negative breast cancers are cancers that don’t have receptors for oestrogen, progesterone or Her2. When it has spread to another part of the body it is called metastatic triple negative breast cancer.

People could join the study between 2015 and 2017. The team published the results in 2021.

There is a link to more information in the ‘Summary of results’ section below.